e Iron acquisition is crucial for the growth of Aspergillus fumigatus. A. fumigatus biofilm formation occurs in vitro and in vivo and is associated with physiological changes. In this study, we assessed the effects of Fe chelators on biofilm formation and development. Deferiprone (DFP), deferasirox (DFS), and deferoxamine (DFM) were tested for MIC against a reference isolate via a broth macrodilution method. The metabolic effects (assessed by XTT [2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt]) on biofilm formation by conidia were studied upon exposure to DFP, DFM, DFP plus FeCl 3 , or FeCl 3 alone. A preformed biofilm was exposed to DFP with or without FeCl 3 . The DFP and DFS MIC 50 against planktonic A. fumigatus was 1,250 M, and XTT gave the same result. DFM showed no planktonic inhibition at concentrations of <2,500 M. By XTT testing, DFM concentrations of <1,250 M had no effect, whereas 2,500 M increased biofilms forming in A. fumigatus or preformed biofilms (P < 0.01). DFP at 156 to 2,500 M inhibited biofilm formation (P < 0.01 to 0.001) in a dose-responsive manner. Biofilm formation with 625 M DFP plus any concentration of FeCl 3 was lower than that in the controls (P < 0.05 to 0.001). FeCl 3 at >625 M reversed the DFP inhibitory effect (P < 0.05 to 0.01), but the reversal was incomplete compared to the controls (P < 0.05 to 0.01). For preformed biofilms, DFP in the range of >625 to 1,250 M was inhibitory compared to the controls (P < 0.01 to 0.001). FeCl 3 at >625 M overcame inhibition by 625 M DFP (P < 0.001). FeCl 3 alone at >156 M stimulated biofilm formation (P < 0.05 to 0.001). Preformed A. fumigatus biofilm increased with 2,500 M FeCl 3 only (P < 0.05). In a strain survey, various susceptibilities of biofilms of A. fumigatus clinical isolates to DFP were noted. In conclusion, iron stimulates biofilm formation and preformed biofilms. Chelators can inhibit or enhance biofilms. Chelation may be a potential therapy for A. fumigatus, but we show here that chelators must be chosen carefully. Individual isolate susceptibility assessments may be needed.A spergillus fumigatus, the ubiquitous saprophytic mold, frequently causes respiratory tract infections, including invasive pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (1). A. fumigatus disease occurs most frequently in immunocompromised individuals, such as bone marrow transplant and other neutropenic patients, solid organ transplant recipients (2), and in those with cystic fibrosis (1, 3), chronic granulomatous disease, or chronic obstructive pulmonary disease (1, 4). Despite therapeutic advances in the development and administration of antifungals, mortality from A. fumigatus infection remains high (5).A. fumigatus has shown, in vivo and in vitro, the ability to form biofilms, or complex aggregates of organisms embedded within a polymer-rich extracellular matrix, which demonstrate increased antimicrobial resistance (32). Thus, there is a need for other therapeutic methods with mechanisms that d...